Journal articles: 'Boston University Medical School'

1

Cohn, Amy, Sarah Root, Carisa Kymissis, Justin Esses, and Niesha Westmoreland. "Scheduling Medical Residents at Boston University School of Medicine." Interfaces 39, no. 3 (June 2009): 186–95. http://dx.doi.org/10.1287/inte.1080.0369.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Farber, Harrison, Richard M. Silver, Virginia D. Steen, and Charles Strange. "Pulmonary Arterial Hypertension Associated With Scleroderma." Advances in Pulmonary Hypertension 7, no. 2 (April 1, 2008): 301–8. http://dx.doi.org/10.21693/1933-088x-7.2.301.

Full text

Abstract:

This discussion was moderated by Harrison (Hap) Farber, MD, Professor, Department of Medicine, Boston University School of Medicine, and Director, Pulmonary Hypertension Center, Boston Medical Center, Boston, Massachusetts. Panel members included Richard M. Silver, MD, Professor of Medicine and Pediatrics and Director of the Division of Rheumatology and Immunology, Medical University of South Carolina, Charleston, South Carolina; Virginia D. Steen, MD, Proffessor of Medicine, Georgetown University, Washington, DC; and Charles Strange, MD, Professor of Pulmonary Medicine, Division of Pulmonary and Critical Care Medicine, Medical University of South Carolina, Charleston, South Carolina.

APA, Harvard, Vancouver, ISO, and other styles

3

Farber, Harrison W., Mark Gladwin, Evelyn M. Horn, and Myung H. Park. "Sickle Cell Disease and Pulmonary Hypertension: Addressing the Mixed Pathology and Special Considerations in Diagnosis and Treatment." Advances in Pulmonary Hypertension 6, no. 1 (January 1, 2007): 39–44. http://dx.doi.org/10.21693/1933-088x-6.1.39.

Full text

Abstract:

This discussion was moderated by Evelyn M. Horn, MD, Associate Professor of Clinical Medicine and Director, Pulmonary Vascular Disease, Center for Advanced Cardiac Care, Columbia University Medical Center, New York, New York. Panel members included Harrison W. Farber, MD, Director, Pulmonary Hypertension Center, Boston Medical Center, Boston University School of Medicine; Mark Gladwin, MD, Chief, Vascular Medicine Branch, National Heart, Lung, and Blood Institute, Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, MD; Myung H. Park, MD, Director, Pulmonary Vascular Disease Program, University of Maryland School of Medicine.

APA, Harvard, Vancouver, ISO, and other styles

4

N/A. "Boston University Names John McCahan Acting Dean of the Medical School." Journal Of Investigative Medicine 52, no. 03 (2004): 155. http://dx.doi.org/10.2310/6650.2004.0001d.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Ronan, Matthew V., Aravind Menon, Lakshman Swamy, and David Thornton. "Experiential Learning Through Local Implementation of a National Chief Resident in Quality and Patient Safety Curriculum." American Journal of Medical Quality 35, no. 2 (June 27, 2019): 171–76. http://dx.doi.org/10.1177/1062860619859076.

Full text

Abstract:

The Clinical Learning Environment Review was created to evaluate quality improvement and patient safety (QIPS) beginning in 2013. Little guidance has been offered on implementing QIPS curricula for residency education. The aim was to provide a model QIPS residency curriculum from VA Boston Healthcare System (VABHS), wherein a chief resident in quality and patient safety (CRQS) participates in a national curriculum implementing skills and concepts locally. The CRQS mentors a patient safety resident with faculty oversight. The program involves case investigations, educational conferences, and experiential learning. Participants are residents from Beth Israel Deaconess Medical Center, Boston Medical Center, and Brigham and Women’s Hospital and medical students from Boston University Medical School and Harvard Medical School. Local and national CRQS programs are evaluated. The patient safety rotation is evaluated locally. The local curriculum at VABHS augments the national curriculum and deploys a patient safety education that develops experiential learning skills.

APA, Harvard, Vancouver, ISO, and other styles

6

Barnes, Linda L., Lance D. Laird, and Bayla Ostrach. "From Medical Anthropology at a Medical School to Careers in Community-Based Applied Anthropology." Practicing Anthropology 42, no. 1 (January 1, 2020): 36–42. http://dx.doi.org/10.17730/0888-4552.42.1.36.

Full text

Abstract:

Abstract This article discusses the origins and development of the MS Program in Medical Anthropology in the Division of Graduate Medical Sciences at Boston University School of Medicine. We review how our faculty identified the need for the program as well as how we developed its design and negotiated the degree curriculum and requirements. We trace the evolution of our Service-Learning Internship Program (SLIP) and its establishment at various facilities. Finally, we discuss how we translated anthropological research paradigms to clinical settings and how the degree experience has translated into careers in community-based anthropology.

APA, Harvard, Vancouver, ISO, and other styles

7

Alexeevich, Andreev Alexander, and Anton Petrovich Ostroushko. "Joseph Edward MURRAY - American surgeon-transplant surgeon, academician of the National Academy of Sciences of the United States (to the 100th of birthday)." Journal of Experimental and Clinical Surgery 12, no. 1 (March 2, 2019): 81. http://dx.doi.org/10.18499/2070-478x-2019-12-1-81-81.

Full text

Abstract:

Joseph Murray was born in 1919 in the USA. He graduated from the College of the Holy Cross and Harvard University Medical School. He developed his own method of kidney transplantation, proposed to reduce the risk of immune rejection of the organ by performing closely related transplants. In 1954, D. Murray completed the first successful kidney transplant in the world from a twin brother, in 1959 from an unrelated donor, in 1962 from a deceased donor. In 1971, Murray returned to the study of plastic surgery, being the chief plastic surgeon at the Children's Hospital of Boston from 1972 to 1985. In 1986, he left the surgical practice, having the honorary title of professor at Harvard University Medical School. In 1990, Joseph Murray, along with Edward Thomas was awarded the Nobel Prize in Medicine. In the same year, Joseph Murray was admitted to the Pontifical Academy of Sciences, in 1993 - the National Academy of Sciences of the USA. Joseph Edward Murray died in 2012 in the city of Boston.

APA, Harvard, Vancouver, ISO, and other styles

8

Angel, Jonathan B. "HIV Cure Research: An example of successful advocacy by scientists for science." Clinical and Investigative Medicine 41 (November 3, 2018): 14–16. http://dx.doi.org/10.25011/cim.v41i2.31416.

Full text

Abstract:

Following medical school and an internal medicine residency in Toronto, and infec-tious diseases training at the New England Medical Center/Tufts University in Boston, Jonathan joined the Division of Infectious Diseases, Department of Medicine at the Ottawa General Hospital in 1995. His research focuses on understanding how HIV damages the immune system and how these insights may lead to new therapies. Jon-athan is currently Professor of Medicine, University of Ottawa and Senior Scientist, Ottawa Hospital Research Institute. He was Editor-in-Chief of CIM from 2010–2015.

APA, Harvard, Vancouver, ISO, and other styles

9

Morley, T. P. "Kenneth Edwin Livingston M.D., D.A.B.N., F.A.C.S., F.R.C.S. (C) (1914 – 1984)." Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques 12, no. 1 (February 1985): 76. http://dx.doi.org/10.1017/s0317167100046655.

Full text

Abstract:

Kenneth Livingston was born in 1914 in Pendleton, Oregon. He attended Stanford University and obtained his BA in 1936. His medical student days were spent at Harvard where he graduated MD in 1939.His neurosurgical education began in 1942 at Strong Memorial Hospital, Rochester, N.Y.; then, after two years at the U.S. Naval Hospital in Oakland, California, he was appointed to the Attending Staff at the Lahey Clinic in Boston from 1946-1948. He returned to Oregon as Assistant Clinical Professor of Neurosurgery at the University of Oregon Medical School in 1948.

APA, Harvard, Vancouver, ISO, and other styles

10

Oudiz, Ronald J., Robert Naeije, Virginia D. Steen, Hunter C. Champion, and David Systrom. "Controversies and Consensus: Identifying the Key Issues in Exercise Testing." Advances in Pulmonary Hypertension 7, no. 4 (December 1, 2008): 412–17. http://dx.doi.org/10.21693/1933-088x-7.4.412.

Full text

Abstract:

This discussion was moderated by Ronald J. Oudiz, MD, Associate Professor of Medicine, UCLA School of Medicine and Director, Liu Center for Pulmonary Hypertension, Division of Cardiology, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California. Participants included: Hunter C. Champion, MD, PhD, Assistant Professor, Department of Medicine, Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore, Maryland; Robert Naeije, MD, PhD, Professor and Chairman of the Department of Physiology and Pathophysiology at Erasme University Hospital, Brussels, Belgium; Virginia D. Steen, MD, Professor of Medicine and Director of the Rheumatology Fellowship Program, Georgetown University School of Medicine, Washington, DC; and David Systrom, MD, Director, Cardiopulmonary Exercise Lab, Department of Medicine, Pulmonary Critical Care, Massachusetts General Hospital, Boston, Massachusetts.

APA, Harvard, Vancouver, ISO, and other styles

11

Thornton, Christina S., Michael B. Keough, Jodie I. Roberts, Bryan Yipp, Morley Hollenberg, Jason T. Bau, Michael A. Peplowski, and Paul L. Beck. "Proceedings from the 5th Annual University of Calgary Leaders in Medicine Research Symposium." Clinical & Investigative Medicine 37, no. 5 (October 4, 2014): 292. http://dx.doi.org/10.25011/cim.v37i5.22010.

Full text

Abstract:

On November 8, 2013, the Leaders in Medicine (LIM) program hosted the 5th Annual Research Symposium. Dr. Jerrold Ellner, Chief of the Infectious Diseases section at Boston Medical Centre and Professor of Medicine at Boston University School of Medicine, was the keynote speaker and presented his lecture entitled “Tuberculosis – Past, Present and Future”. The LIM symposium gives a forum for LIM as well as non-LIM medical students to present their research work as either an oral or poster presentation. There were a total of 53 abstracts presented and five oral presentations. The symposium was attended by over 100 students and more than 30 staff members. The oral presentations included • Amrita Roy, Aboriginal identity, ethnic minority status, and prenatal depressive symptoms in a longitudinal pregnancy cohort study in Alberta. • David Nicholl, Obstructive sleep apnea treatment with continuous positive airway pressure decreases intraglomerular pressure and alters renal sensitivity to angiotensin. • James Cotton, An assemblage A Giardia cathepsin B protease degrades interleukin-8 and attenuates neutrophil chemotaxis. • Krystyna Ediger, Alexander Arnold and Emily Shelton, Rebuilding the Calgary Student Run Clinic: A Model for Sustainability. • Sarah MacEachern, Inhibiting inducible nitric oxide synthase restores electrogenic ion transport in experimental IBD: a novel role for enteric glia. See the article on the University of Calgary Leaders in Medicine Program, “A Prescription that Addresses the Decline of Basic Science Education in Medical School” in this same issue of CIM for more details on the program. In short, the LIM Research Symposium has the following objectives: (1) to showcase the impressive variety of projects undertaken by students in the LIM Program as well as U of C medical students; (2) to encourage medical student participation in research and special projects; and, (3) to inform students and faculty about the diversity of opportunities available for research and special projects during medical school and beyond. The following abstracts are those that were put forward for publication.

APA, Harvard, Vancouver, ISO, and other styles

12

Schoettler, Cynthia L., Jennifer N. Lee, Kathy A. Ireland, and Carine M. Lenders. "A Novel Method of Increasing Medical Student Nutrition Awareness and Education." Journal of Biomedical Education 2015 (August 5, 2015): 1–8. http://dx.doi.org/10.1155/2015/784042.

Full text

Abstract:

Medical nutrition education in most US medical schools is lacking, despite an epidemic of lifestyle related chronic conditions and high rates of malnutrition in hospitals. In a unique response to this deficit, students at Boston University School of Medicine have created a novel student interest group entitled Student Nutrition Awareness and Action Council (SNAAC). This student group is unique in that it focuses on interprofessional collaboration and development of concrete practice skills and works to fill educational gaps. The goal of SNAAC is to increase medical student knowledge, attitude, and skills in medical nutrition through providing extracurricular activities and partnering with official medical school curriculum committees. To accomplish this, SNAAC has developed a multipartite group overseen by a mentoring team composed of a physician nutrition specialist, registered dietitian, and a mental health provider. SNAAC provides nutrition oriented opportunities for members and the student body at large. Participation is high because it fills an educational gap, offers a unique focus on expanding nutrition awareness and education, and provides opportunities for student leadership and professional development. We encourage other medical schools to use the SNAAC student involvement model to increase nutrition awareness and facilitate the incorporation of medical nutrition in their curriculum.

APA, Harvard, Vancouver, ISO, and other styles

13

Isner, Jeffrey M., Ken Walsh, Kenneth Rosenfield, Robert Schainfeld, Takayuki Asahara, Kathleen Hogan, and Ann Pieczek. "Arterial Gene Therapy for Restenosis. St. Elizabeth's Medical Center, Tufts University School of Medicine, Boston, Massachusetts." Human Gene Therapy 7, no. 8 (May 20, 1996): 989–1011. http://dx.doi.org/10.1089/hum.1996.7.8-989.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Fagan, Karen A., Kamal K. Mubarak, Zeenat Safdar, Aaron Waxman, and Roham T. Zamanian. "Expanded Use of PAH Medications." Advances in Pulmonary Hypertension 7, no. 1 (January 1, 2008): 249–54. http://dx.doi.org/10.21693/1933-088x-7.1.249.

Full text

Abstract:

This discussion was moderated by Karen A. Fagan, MD, Professor and Director, Division of Pulmonary Medicine, University of South Alabama College of Medicine, Mobile, Alabama. Panel members included Kamal K. Mubarak, MD, Assistant Professor of Medicine, Director, Pulmonary Hypertension Clinic, Wayne State University, Detroit, Michigan; Zeenat Safdar, MD, Assistant Professor of Medicine, Department of Medicine, Section of Pulmonary, Critical Care, and Sleep Medicine, Baylor College of Medicine, Houston, Texas; Aaron Waxman, MD, PhD, Associate Professor of Medicine, Harvard Medical School, Director, Pulmonary Vascular Disease Program and Pulmonary Critical Care Unit, Massachusetts General Hospital, Boston, Massachusetts; and Roham T. Zamanian, MD, Assistant Professor of Medicine, Director, Adult Pulmonary Hypertension Clinical Service, Vera Moulton Wall Center for Pulmonary Vascular Disease, Stanford University School of Medicine, Stanford, California.

APA, Harvard, Vancouver, ISO, and other styles

15

Berman, Jason. "Model organisms—the critical link between gene discovery and therapeutic intervention." Clinical and Investigative Medicine 41 (November 3, 2018): 21–23. http://dx.doi.org/10.25011/cim.v41i2.31422.

Full text

Abstract:

Jason graduated from the University of Toronto Medical School in 1997 followed by a pediatric residency at the Hospital for Sick Children, a fellowship in pediatric hematology/oncology at Boston Children’s Hospital and post-doctoral training at the Dana-Farber Cancer Institute. He is a professor at Dalhousie University in the Departments of Pediatrics, Microbiology and Immunology and Pathology, was appointed as the director of the Clinician Investigator Program (CIP) and the Graduate Program in Medical Research at Dalhousie (2014), elected president of the Canadian Society for Clinical Investigation (CSCI) (2017) and currently serves as Associate Chair Research in the Department of Pediatrics and Interim VP Research at the IWK, and as an assistant editor of the Journal of Clinical and Investigative Medicine (CIM).

APA, Harvard, Vancouver, ISO, and other styles

16

Buescher, Thomas M., and Howard Gardner. "Seeking the Roots of Talent: An Interview with Howard Gardner." Journal for the Education of the Gifted 8, no. 3 (April 1985): 179–86. http://dx.doi.org/10.1177/016235328500800302.

Full text

Abstract:

What do we know about the origins of talent and its relationship to the artistic products of children? While a number of psychologists, philosophers, educators, and artists have taken diverse paths to locate the roots of talent, few have been as insightful or persistent in that quest as Howard Gardner. JEG interviewed Dr. Gardner in November, 1984, following the publication of his newest book, Frames of Mind, which argues the case for a theory of multiple intelligences (or talents). Dr. Gardner is a prolific writer and researcher who was named as a MacArthur Foundation Fellow in 1981. He continues to serve as Co-Director of Harvard Project Zero in Cambridge, Massachusetts, as research scientist in neuropsychology at the Boston Veterans Administration Medical Center, and as Professor of Neurology, Boston University School of Medicine.

APA, Harvard, Vancouver, ISO, and other styles

17

Rehder, Roberta, Subash Lohani, and Alan R. Cohen. "Unsung hero: Donald Darrow Matson’s legacy in pediatric neurosurgery." Journal of Neurosurgery: Pediatrics 16, no. 5 (November 2015): 483–94. http://dx.doi.org/10.3171/2015.4.peds156.

Full text

Abstract:

Donald Darrow Matson made seminal contributions to the field of pediatric neurosurgery. Born in 1913 in Fort Hamilton, New York, Matson was the youngest of four sons of an army colonel. He graduated from Cornell University and, years later, from Harvard Medical School. Matson selected Peter Bent Brigham Hospital for his neurosurgical training, which was interrupted during World War II. As a neurosurgeon, he worked close to the front lines under Brigadier General Elliot Cutler in Europe, earning a Bronze Star. Matson returned to Boston to become Franc Ingraham’s fellow and partner. He was a masterful surgeon and, with Ingraham, published Neurosurgery of Infancy and Childhood in 1954, the first pediatric neurosurgery textbook in the world. Upon Ingraham’s retirement, Matson became chairman of the department of neurosurgery at Boston Children’s Hospital and Peter Bent Brigham. In 1968, he became the inaugural Franc D. Ingraham Professor of Neurological Surgery at Harvard Medical School. Among his neurosurgical accomplishments, Matson served as President of the Harvey Cushing Society, later known as the American Association of Neurological Surgeons. He was unable to preside at the 1969 meeting that marked the 100th anniversary of Cushing’s birth, having contracted Creutzfeldt-Jakob disease. Matson died at the age of 55, surviving his mentor Ingraham by only 4 years.

APA, Harvard, Vancouver, ISO, and other styles

18

Koenders, Sedona L., Linda L. Barnes, Lance D. Laird, Bayla Ostrach, and Gemmae M. Fix. "Applied Training in a Medical Anthropology Master's Program." Practicing Anthropology 42, no. 1 (January 1, 2020): 43–47. http://dx.doi.org/10.17730/0888-4552.42.1.43.

Full text

Abstract:

Abstract Learning practical skills is key to becoming an applied anthropologist. For my MS degree, I chose a program at Boston University School of Medicine that incorporates skills development into the curriculum through its Service-Learning Internship Program (SLIP). The SLIP facilitates students' familiarity with their field site throughout the first year, before they start summer fieldwork. My SLIP and thesis fieldwork took place in a VA hospital's pain clinic—a placement ideal for my interest in researching pain management during an opioid epidemic. This paper describes my training, developing a research question, meeting theoretical and logistical requirements, handling the unpredictable nature of research, data collection, analysis, and writing. I use getting Institutional Review Board (IRB) approval for my thesis project as an example of how these skills came together. Guided by my mentors, this experience afforded me hands-on training. I can now bring my anthropological approach into the work force.

APA, Harvard, Vancouver, ISO, and other styles

19

White, R. James, Mardi Gomberg-Maitland, Jeremy Feldman, Ioana Preston, and Steve Mathai. "Imatinib: A Perspective on Its Potential for PAH Patients." Advances in Pulmonary Hypertension 11, no. 1 (January 1, 2012): 41–46. http://dx.doi.org/10.21693/1933-088x-11.1.41.

Full text

Abstract:

We invited 4 experts to a telephone roundtable facilitated by guest editor Jim White, MD, PhD, on April 13, 2012, to discuss the results of the recent Phase III trial, the Imatinib in Pulmonary Arterial Hypertension (IMPRES) trial (NCT00902174). Investigators enrolled patients with pulmonary arterial hypertension with severe hemodynamic impairment at catheterization despite treatment with 2 background therapies. Patients were randomized to placebo or 200 mg imatinib twice daily for 6 months of therapy to assess efficacy. Participating in the discussion were Mardi Gomberg-Maitland, MD, MSc, Associate Professor of Medicine and Director, Pulmonary Hypertension Center, University of Chicago; Iona Preston, MD, Co-director, Pulmonary Hypertension Center, Tufts University Medical Center, Boston; Jeremy Feldman, MD, Director, Pulmonary Hypertension Program, Medical Director of Research, Arizona Pulmonary Specialists, Phoenix; Stephen Mathai, MD, MHS, Assistant Professor of Medicine, The Johns Hopkins School of Medicine, Baltimore.

APA, Harvard, Vancouver, ISO, and other styles

20

Barst, Robyn, David Wessel, Nancy Bridges, and Dunbar Ivy. "Pulmonary Arterial Hypertension in Congenital Heart Disease: Controversies and Consensus." Advances in Pulmonary Hypertension 2, no. 2 (April 1, 2003): 20–25. http://dx.doi.org/10.21693/1933-088x-2.2.20.

Full text

Abstract:

Four physicians discussed current and future strategies for the assessment and treatment of pulmonary arterial hypertension (PAH) related to congenital heart disease. The roundtable discussion was moderated by Robyn Barst, MD, Professor of Pediatrics, Columbia University College of Physicians and Surgeons, New York, New York, and included David Wessel, MD, Professor of Pediatrics and Anesthesia, Harvard Medical School, and Senior Associate in Cardiology and Anesthesia at Children's Hospital, Boston; Nancy Bridges, MD, Chief of the Clinical Transplantation Section, National Institute for Allergy and Infectious Disease, National Institutes of Health, Bethesda, Maryland; and Dunbar Ivy, MD, Associate Professor of Pediatrics, Chief and Selby Rickenbaugh Chair of Pediatric Cardiology, Director of the Pediatric Pulmonary Hypertension Program, University of Colorado, and Denver Children's Hospital.

APA, Harvard, Vancouver, ISO, and other styles

21

Corse, Teija, Chelsea Firth, John Burke, Kenneth Schor, James F. Koterski, Sabrina McGraw, Nancy Vincent-Johnson, and Lori Gordon. "Operation Canine Lifeline: Recommendations for Enhancing Prehospital Care for Government Working Dogs." Disaster Medicine and Public Health Preparedness 11, no. 1 (December 15, 2016): 15–20. http://dx.doi.org/10.1017/dmp.2016.171.

Full text

Abstract:

AbstractOperation Canine Lifeline was a tabletop exercise developed by students and faculty of Boston University School of Medicine’s Healthcare Emergency Management master’s program. The tabletop exercise led to discussion on current protocols for canines working in the field, what occurs if a canine encounters a toxin in the field, and what to do in situations of national security that require working with civilian agencies. This discussion led to the creation of a set of recommendations around providing prehospital veterinary care to government working dogs. The recommendations include a government-run veterinary toxicology hotline for the sole use of the government, issuing handlers deployment kits and preprogrammed smartphones that contain information on the care practices for dogs, and an increased effort for civilian integration, through local emergency medical services, in the emergency care of government canines. (Disaster Med Public Health Preparedness. 2017;11:15–20)

APA, Harvard, Vancouver, ISO, and other styles

22

Isner, Jeffrey M., Ken Walsh, James Symes, Ann Pieczek, Satoshi Takeshita, Jason Lowry, Kenneth Rosenfield, Lawrence Weir, Edi Brogi, and Dan Jurayj. "Arterial Gene Transfer for Therapeutic Angiogenesis in Patients with Peripheral Artery Disease. St. Elizabeth's Medical Center, Tufts University School of Medicine, Boston, Massachusetts." Human Gene Therapy 7, no. 8 (May 20, 1996): 959–88. http://dx.doi.org/10.1089/hum.1996.7.8-959.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Haynes, Christy L. "Surface-Enhanced Raman Scattering: Physics and Applications Edited by Katrin Kneipp (Harvard University Medical School, Boston), Martin Moskovits (University of California, Santa Barbara), and Harald Kneipp (Harvard University Medical School). Springer: Berlin, Heidelberg, New York. 2006. xviii + 464 pp. $219.00. ISBN 3-540-33566-8." Journal of the American Chemical Society 129, no. 7 (February 2007): 2197–98. http://dx.doi.org/10.1021/ja069825k.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Green, Pamela. "2008 Benjamin Franklin medal in life science is Presented to Victor Ambros, Ph.D. (University of Massachusetts Medical School, Worcester, Massachusetts), Gary Ruvkun, Ph.D. (Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts) and David Baulcombe, Ph.D., FRS (University of Cambridge, Cambridge, UK)." Journal of the Franklin Institute 348, no. 3 (April 2011): 500–505. http://dx.doi.org/10.1016/j.jfranklin.2010.05.004.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Genina, E. S., and B. B. Fuks. "BIOGRAPHY OF SURGEON B. I. FUKS IN THE CONTEXT OF THE SOVIET ERA HISTORY." Bulletin of Kemerovo State University, no. 4 (January 10, 2018): 36–45. http://dx.doi.org/10.21603/2078-8975-2017-4-36-45.

Full text

Abstract:

The authors of this article aimed at reconstructing the biography of B. I. Fuks in the context of the history of the Soviet era and its most important events. Boris Ilyich (Ber Eljich) Fuks (1897–1973) was a Doctor of Medical Sciences, Professor, a surgeon, the founder of Novokuznetsk Surgical School. His scientific and pedagogical activity was primarily connected with the Tomsk State University and the State Institute for Advanced Training of Doctors, consistently located in Tomsk, Novosibirsk, Stalinsk (Novokuznetsk). The research is based on the documents found in the State Archives of the Russian Federation, the State Archives of Tomsk Region, the State Archives of Kemerovo Region, the State Archives of Kemerovo Region in Novokuznetsk, and the Archives of Novokuznetsk State Institute for Advanced Training of Doctors, and some publications in the central and local periodicals. The documents from the personal archive and memoirs of B. B. Fuks, the son of B. I. Fuks (Boston, USA), made up a separate important set of sources.

APA, Harvard, Vancouver, ISO, and other styles

26

Guenter, Peggi. "Micronutrients and HIV-1 disease progression MK BAUM, G SHOR-POSNER, Y LU, ET AL University of Miami School of Medicine, Florida; Harvard Medical School, Brigham and Women's Hospital, Boston; and University of Alabama at Birmingham." Nutrition in Clinical Practice 11, no. 2 (April 1996): 77–78. http://dx.doi.org/10.1177/088453369601100209.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Tretter, Justin T., and Jeffrey P. Jacobs. "Global Leadership in Paediatric and Congenital Cardiac Care: “Using data to improve outcomes – an interview with Jennifer S. Li, MD, MHS”." Cardiology in the Young 30, no. 9 (September 2020): 1226–30. http://dx.doi.org/10.1017/s1047951120002875.

Full text

Abstract:

AbstractDr. Jennifer Li is the focus of our second in a planned series of interviews in Cardiology in the Young entitled, “Global Leadership in Paediatric and Congenital Cardiac Care”. Dr. Li was born in Boston, Massachusetts, United States of America, and moved to Indianapolis, Indiana where she completed her secondary education. She then attended Stanford University, majoring in Chemistry and English and graduating with distinction in 1983. Dr. Li then attended Duke University School of Medicine, graduating in 1987. She then completed her internship at Children’s Hospital of Philadelphia in 1987–1989, returning to Duke University Medical Center to complete both her residency in general paediatrics in 1989–1990 followed by her fellowship in paediatric cardiology in 1990–1993. She would later complete her Master’s Degree in Health Sciences at Duke University in 2005.Dr. Li has spent her entire career as a paediatric cardiologist at Duke University Medical Center, where she was appointed a Professor of Pediatrics and Professor of Medicine in 2008 and has held the position as Beverly C. Morgan Endowed Professor of Pediatrics since 2012. She has served as the Chief of Paediatric Cardiology at Duke University Medical Center since 2006. She also was the Director of Paediatric Research at Duke Clinical Research Institute from 2001-2015. Dr. Li has played an instrumental role in evaluating the safety and efficacy of drugs in children, as well as in analysing and linking large multicentric databases to evaluate the outcomes, quality, and cost of paediatric and congenital cardiac care. Dr. Li has received funding from the National Institute of Health of the United States of America, as well as from industry and foundation grants. This article presents our interview with Dr. Li, an interview that covers her experience collaborating with governmental organizations and industry in the pursuit of common interests to design clinical drug trials, link and analyse large, multicentric databases, and improve paediatric health care.

APA, Harvard, Vancouver, ISO, and other styles

28

Galloway, Ann-Christe. "Grants and Acquisitions." College & Research Libraries News 78, no. 8 (September 7, 2017): 467. http://dx.doi.org/10.5860/crln.78.8.467.

Full text

Abstract:

The Washington University Libraries Film and Media Archive has received a grant from the National Film Preservation Foundation to preserve Code Blue, a 1972 recruitment film aimed at bringing minorities into the medical profession. Code Blue is one of the earliest existing films created by Henry Hampton’s Boston-based documentary company Blackside Inc., which produced the Emmy Award-winning civil rights series Eyes on the Prize. Blackside became the largest African American-owned film production company of its time and was home to many filmmakers from diverse backgrounds, including African Americans, immigrants, and women. The 27-minute documentary includes footage from an emergency room in Harlem, a tour through areas of Nashville with a doctor who did outreach to poor families, and discussions with young men and women from different backgrounds who could explain the value of medical education. Code Blue helped to bring new talent into the medical field and was used in hundreds of high schools and medical training curricula nationwide for more than 20 years. The film won a CINE Golden Eagle Award and was seen around the world, including at film festivals as far away as Venice’s Festival dei Popoli.

APA, Harvard, Vancouver, ISO, and other styles

29

Schnaue-Constantouris, Eileen M., Richard B. Birrer, Patrick J. Grisafi, and Michael P. Dellacorte. "Digital foot trauma: emergency diagnosis and treatment 1 1Clinical Communications (Adults) is coordinated by Ron M. Walls, md, of Brigham and Women’s Hospital and Harvard University Medical School, Boston, Massachusetts." Journal of Emergency Medicine 22, no. 2 (February 2002): 163–70. http://dx.doi.org/10.1016/s0736-4679(01)00458-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Chevalier, Lydia, Emily Pariseau, Kristin Long, David Langer, and Donna Pincus. "608 Efficacy of a Treatment for Sleep-Related Problems in Children with Anxiety: A Mixed Methods Study." Sleep 44, Supplement_2 (May 1, 2021): A239. http://dx.doi.org/10.1093/sleep/zsab072.606.

Full text

Abstract:

Abstract Introduction School-aged children with anxiety frequently experience sleep-related problems (SRPs) such as bedtime resistance. Results are mixed, but some children with anxiety also report longer sleep onset latency (SOL). Despite the link between SRPs and mental and physical health consequences, limited research has evaluated the efficacy of brief sleep treatments in this population. Methods A mixed methods approach employing a multiple-baseline single-case design and qualitative methods was used to evaluate the efficacy of a four-session parent training intervention in ten children with anxiety and chronic insomnia (M=9.6 years, range 8–12 years, 8 female). Questionnaires on SRPs and anxiety were completed by parents and children at baseline, one-week post-treatment, and one-month follow-up assessments. Subjective SOL (i.e., sleep diary) and objective SOL (i.e., actigraphy) were measured daily during assessment and treatment weeks. Parents and children completed qualitative interviews at the post-treatment assessment. Results The majority of participants no longer met criteria for chronic insomnia at post-treatment (n=9) or follow-up (n=6). SRPs (e.g., bedtime resistance) were significantly less frequent at post-treatment and follow-up than at baseline. The majority of participants demonstrated significant reductions in subjective (n=7) but not objective (n=3) SOL at post-treatment or follow-up compared to baseline. Qualitatively, parents and children described improvements in sleep during treatment. Some parents described discovering while completing sleep diaries that their child believed themselves to be taking longer to fall asleep at the beginning of treatment than they actually were (i.e., sleep misperception), and that this sleep misperception improved during treatment. Conclusion The findings of the current study support the preliminary efficacy of a brief parent training intervention to treat SRPs in school-aged children with anxiety. They also begin to help elucidate mixed findings in the literature on sleep of children with anxiety by providing a potential reason for discrepancies between subjective and objective SOL in this population. Specifically, qualitative findings suggest that this discrepancy may be related to sleep misperception, that children with anxiety may feel themselves to be taking a long time to fall asleep even when objective measures of SOL are within the normative range. Support (if any) Boston University Clara Mayo Memorial Research Fellowship

APA, Harvard, Vancouver, ISO, and other styles

31

Salimi, Qasim, Thayer Nasereddin, Neel Patel, Reza Hashemipour, Augustine Tawadros, Zamir Brelvi, and Sushil Ahlawat. "The New Jersey Bowel Preparation Scale: A More Objective and Detailed Scoring System for Screening Colonoscopies." Gastroenterology Research and Practice 2019 (March 6, 2019): 1–6. http://dx.doi.org/10.1155/2019/8319747.

Full text

Abstract:

Goals. The goal of this study was to develop an objective and detailed scoring system to assess the quality of bowel preparation. Background. The quality of bowel preparation impacts the success of the colonoscopy. We developed and compared a new bowel preparation scoring system, the New Jersey Bowel Preparation Scale (NJBPS), with existing systems that are limited by a lack of detail and objectivity in the Boston Bowel Preparation Scale (BBPS) and the Ottawa Bowel Preparation Scale (OBPS). Methods. This was a single-center, prospective, dual-observer study performed at Rutgers New Jersey Medical School University Hospital. Patients who were at medium risk for colorectal cancer and undergoing outpatient screening colonoscopy were enrolled in the study, and their bowel preparation was assessed separately by an attending and a fellow using each of the bowel preparation scoring systems. Results. 98 patients were analyzed in the study, of which 59% were female. Most of the patient population was African American (65%) or Hispanic (25%). The average age of the patient was 60 years. Chi-squared analysis using SPSS software revealed intraclass correlation coefficient values between attending and fellow scores for each scale. The NJBPS had the highest value at 0.988, while the BBPS and OBPS had values of 0.883 and 0.894. Limitations. Single-center study. Conclusions. The NJBPS and BBPS scores demonstrated a statistically significant agreement with each other. Overall, there was good interobserver agreement for all three scoring systems when comparing attendings to fellows for the same scoring system. However, the NJBPS possessed a stronger correlation.

APA, Harvard, Vancouver, ISO, and other styles

32

Abdelaal, Mahmoud A. Z., Dyala Abdelrahman, Mahir Cengiz, Hakan Yavuzer, Serap Yavuzer, Ivy Bien, Preeti Bhuva, et al. "Actions of L-Glutamine vs. COVID-19 Suggest Additional Benefit in Sickle Cell Disease." Blood 136, Supplement 1 (November 5, 2020): 11–12. http://dx.doi.org/10.1182/blood-2020-135903.

Full text

Abstract:

Background:The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection associated with coronavirus disease 2019 (COVID-19) causes a 3- to 9-fold higher age-adjusted mortality in African American and Hispanic populations, the major US racial groups affected by sickle cell disease (SCD). The Centers for Disease Control designates SCD as a condition at increased risk for severe COVID-19. An urgent need for repurposing of available and safe therapeutics has been cited for such high-risk populations until vaccines are widely available. L-glutamine (GLN) ameliorates clinical pathology of SCD related to elements of COVID-19. Multiple systemic complications of COVID-19 are increasingly attributed to oxidative damage, a target which GLN regulates. Prescription-grade L-glutamine (PGLG) (Endari®, Emmaus Medical) decreases oxidative stress by increasing the ratio of reduced nicotinamide adenine dinucleotide (NAD) to total NAD, which may increase availability of reduced glutathione. PGLG also decreases red cell endothelial adhesion in patients with SCD. Of note, additional analysis of the phase 3 trial demonstrated a 63% lower occurrence of acute chest syndrome (ACS) in PGLG-treated SCD patients compared to control, which has important relevance in the pandemic. A recent report of two computational screens of FDA-approved therapeutics, directed to protein and chemistry targets and to gene expression changes induced by SARS-CoV-2, predicts glutathione and GLN are highly likely to confer benefit in COVID-19 (Kim, J Translat Med, 2020). Methods:We therefore reviewed reports of multi-system effects of GLN in experimental respiratory distress animal models and in ICU and COVID-19 patients. We focused on contributors to cytokine storm and acute respiratory distress syndrome (ARDS), the leading causes of mortality in COVID-19 (Huang, Lancet, 2020). We also conducted a clinical trial in hospitalized COVID-19 patients on ESPEN-recommended nutrition +/- GLN. Results:In experimental ARDS, sepsis, and endotoxin-induced lung injury, GLN decreases consolidation, pulmonary edema, and neutrophil infiltration and increases lung compliance, oxygen saturation, heat shock protein activation, and survival by 2.5-fold over saline controls (Perng WC, Clin Exp Pharmacol Physiol, 2010; Singleton, Crit Care Med, 2005). Patients with severe COVID-19 have increased proinflammatory cytokines; interleukin 6 (IL-6) levels predict and contribute to severity of COVID-19 (Yuki, Clin Immunol, 2020). GLN modulates inflammatory responses by suppressing C-reactive protein, IL-6, and TNF-α release; it also reduces IL-6 in murine studies (37% decrease,p< 0.05; Chuang, BMC Pulm Med, 2014), which could benefit COVID-19 patients. Myocardial injury occurs in up to 12% of COVID-19 patients directly with viral entry through ACE-2 receptors, microvascular damage, endothelial shedding, and inflammation-mediated damage, which GLN protects against (Shi, Eur Heart J, 2020; Shi, JAMA Cardiol, 2020; Shao, Pak J Med Sci, 2015). Inflammatory states lead to GLN consumption and negative GLN balance (Santos, Amino Acids, 2019). Deficient plasma GLN (< 420 µmol/L) is a defined risk for higher mortality in ICU and COVID-19 patients (Shen, Cell, 2020). Glutathione deficiency contributes to SARS-CoV-2 oxidative lung damage and severe disease (Polonikov, ACS Infect Dis, 2020). In a recent clinical trial, patients were confirmed to have SARS-CoV-2 by RT-PCR, had positive CT scans, and were admitted from a COVID-19 clinic. Both arms received ESPEN-recommended nutrition for COVID-19 alone or with GLN (10 grams, 3 times/day; see Table). Conclusions:GLN and glutathione deficiency contribute to COVID-19 severity, and GLN has salutary biologic actions on reducing lung pathology, mediators of cytokine storm, and myocardial injury in animal models, SCD, and ICU patients. GLN reduces severity in standard risk COVID-19 patientsafterinfection has occurred. These findings, combined with computational prediction of GLN benefit vs. COVID-19, support the hypothesis that PGLG treatmentprior toSARS-CoV-2 infection mayreducethe development of severe COVID-19 in SCD and perhaps other high-risk populations. The data as a whole provides a strong rationale for a controlled clinical trial of PGLG toreducesevere COVID-19 in high-risk SCD patients and improve outcomes if infection occurs. Disclosures Cengiz: Biruni University Medical Faculty:Current Employment;Istanbul University-Cerrahpasa Medical Faculty:Ended employment in the past 24 months.Yavuzer:Istanbul University-Cerrahpasa, Cerrahpasa School of Medicine, Department of Internal Medicine, Division of Geriatrics:Current Employment.Yavuzer:Biruni University Medical Faculty:Current Employment;Istanbul University-Cerrahpasa Mediacl Faculty:Ended employment in the past 24 months.Tang:Kaiser Permanente:Current Employment.Ward:Emmaus Medical, Inc.:Current Employment.Goodrow:Emmaus Medical, Inc.:Current Employment;Emmaus Life Sciences Shareholder:Current equity holder in publicly-traded company.Ludlum:Emmaus Life Sciences, Inc.:Consultancy, Current equity holder in publicly-traded company.Stark:Emmaus Life Sciences Shareholder:Current equity holder in publicly-traded company;Emmaus Medical, Inc:Current Employment.Perrine:Cetya Inc.:Membership on an entity's Board of Directors or advisory committees;Phoenicia Bioscience:Current Employment, Current equity holder in private company, Membership on an entity's Board of Directors or advisory committees;Phoenicia Therapeutics:Membership on an entity's Board of Directors or advisory committees, Patents & Royalties;Boston University School of Medicine:Current Employment, Patents & Royalties;Viracta Therapeutics:Patents & Royalties.

APA, Harvard, Vancouver, ISO, and other styles

33

Hasegawa, Kohei, Rita K. Cydulka, Ashley F. Sullivan, Mark I. Langdorf, Stephanie A. Nonas, Richard M. Nowak, Nancy E. Wang, and Carlos A. Camargo. "Improved Management of Acute Asthma Among Pregnant Women Presenting to the ED * *From the Department of Emergency Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA; the Department of Emergency Medicine, MetroHealth Medical Center, Case Western Reserve University, School of Medicine, Cleveland, OH; the Department of Emergency Medicine, University of California Irvine Medical Center, Orange, CA; the Division of Pulmonary and Critical Care Medicine, Oregon Health and Science University Hospital, Portland, OR; the Department of Emergency Medicine, Henry Ford Hospital, Detroit, MI; and the Department of Emergency Medicine, Stanford University Medical Center, Stanford, CA." Chest 147, no. 2 (February 2015): 406–14. http://dx.doi.org/10.1378/chest.14-1874.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Carlson, Kristen, Jack Tuszynski, and Ze’ev Bomzon. "CSIG-26. IS INTRINSIC APOPTOSIS THE SIGNALING PATHWAY ACTIVATED BY TUMOR-TREATING FIELDS FOR GLIOBLASTOMA?" Neuro-Oncology 21, Supplement_6 (November 2019): vi49. http://dx.doi.org/10.1093/neuonc/noz175.196.

Full text

Abstract:

Abstract Increasingly, tumor-treating fields (TTFields, 2 V/cm, 200 kHz) are accepted as the fourth treatment modality for glioblastoma. Evidence shows that substituting non-steroidal inflammation control (celecoxib) for dexamethasone increases overall survival from 4.8 to 11.0 months, and more recently, up to 60 months. Toward explaining TTFields mechanism of action (MoA), our numerical simulations indicate that TTFields disrupt functionality of microtubules, which in turn trigger the intrinsic apoptotic pathway independent of cell cycle checkpoints. We present the theory and empirical evidence. 1) TTFields act similarly to chemotherapeutic ‘spindle poisons’ by interfering with microtubule (MT) polymerization, increasing free tubulin by 20% in relative terms; 2) Finite element modeling shows TTFields amplify electric field strength, in accord with empirical results, a) along the MT when aligned with the cell axis, where field strength exceeds 10–16 N required to disrupt motor protein transit, and b) 15x at MT ends when orthogonal to cell axis; 3) Either through producing excess free tubulin, which may block voltage-dependent anion channels, or direct effects on the mitochondrial inner and outer membranes, TTFields inhibit expression of pro-survival protein Bcl-2; 4) Decreased Bcl-2 expression activates the intrinsic apoptotic pathway in a novel cell-cycle-checkpoint and caspase-independent manner; 5) Patients using low (< 4.1 mg/day) vs. high (>4.1 mg/day) dexamethasone doses experienced an average 8.7 vs. 3.2 months OS and up to 60 months; 6) Numerous studies in both brain and other tissues show that dexamethasone a) promotes extrinsic, immune-system apoptosis and b) inhibits intrinsic, Bcl-2/Bax mediated apoptosis; 7) Downstream effects of intrinsic apoptosis are remarkably similar to empirically-observed effects of TTFields on tumor cells. Research supported by Novocure Ltd. Dept of Neurosurgery, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston MA USA. carlsokw@bidmc.harvard.edu. Dept of Physics, University of Alberta, Edmonton, Canada, Novocure Ltd., Haifa, Israel.

APA, Harvard, Vancouver, ISO, and other styles

35

Lang, Carol. "Effectiveness of Orthotopic Liver Transplantation on the Restoration of Cholesterol Metabolism in Patients with End-Stage Liver Disease J. PALOMBO, S. LOPES, S. ZEISEL, R. JENKINS, J. ALBERS, G. BLACKBURN, AND B. BISTRIAN Laboratory of Nutrition and Infection, Cancer Research Institute, New England Deaconess Hospital/Harvard Medical School, and Departments of Pathology and Pediatrics, Boston University School of Medicine, Boston, Massachusetts, and Departments of Medicine and Pathology, Northwest Lipid Research Center, University of Washington School of Medicine Seattle, Washington." Nutrition in Clinical Practice 3, no. 3 (June 1988): 121. http://dx.doi.org/10.1177/088453368800300310.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Garg, Priya S., Rebecca Halley, and Molly Cohen Osher. "Boston University School of Medicine." Academic Medicine 95, no. 9S (September 2020): S220—S222. http://dx.doi.org/10.1097/acm.0000000000003352.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

CULBERT, ARTHUR J. "Boston University School of Medicine." Academic Medicine 75, Supplement (September 2000): S149—S150. http://dx.doi.org/10.1097/00001888-200009001-00044.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Levine, Sharon A. "Boston University School of Medicine." Academic Medicine 85 (September 2010): S265—S268. http://dx.doi.org/10.1097/acm.0b013e3181e91384.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Gilmore, Elizabeth. "Intravenous Tubing Containing Burettes Can Be Safely Changed at 72 Hour Intervals D. SNYDERMAN, M. DONNELLY-REIDY, L. PERRY, AND W. MARTIN Departments of Medicine, Pathology and Epidemiology, Northeast Medical Center, Tufts University School of Medicine, Boston, Massachusetts." Nutrition in Clinical Practice 3, no. 1 (February 1988): 33. http://dx.doi.org/10.1177/088453368800300112.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Mello Udine, Laurie. "Enteral nutrition with supplemental arginine, RNA, and omega-3 fatty acids in patients after operation: Immunologic, metabolic, and clinical outcome JM DALY, MD LIEBERMAN, J GOLDFINE, ET AL University of Pennsylvania, Philadelphia, and Harvard Medical School, Boston, Massachusetts." Nutrition in Clinical Practice 8, no. 2 (April 1993): 82. http://dx.doi.org/10.1177/088453369300800216.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Guilhoto, Laura M. F. Ferreira, Rosangela D. Cruz Fernandes, Sandra Pasquali Pacheco, Denise Ballester, and Alfredo Elias Gilio. "Benign focal seizures of adolescence and neuropsychological findings in patients from community." Journal of Epilepsy and Clinical Neurophysiology 15, no. 4 (December 2009): 184–91. http://dx.doi.org/10.1590/s1676-26492009000400009.

Full text

Abstract:

RATIONALE: Benign focal seizures of adolescence (BFSA) described by Loiseau et al in 1972, is considered a rare entity, but maybe underdiagnosed. Although mild neuropsychological deficits have been reported in patients with benign epilepsies of childhood, these evaluations have not so far been described in BFSA. The aim of this study is to evaluate neuropsychological functions in BFSA with new onset seizures (<12 months). METHODS: Eight patients with BFSA (according to Loiseau et al, 1972, focal or secondarily tonic clonic generalized seizures between the ages of 10-18 yrs., normal neurologic examination, normal EEG or with mild focal abnormalities) initiated in the last 12 months were studied between July 2008 to May 2009. They were referred from the Pediatric Emergency Section of the Hospital Universitário of the University of Sao Paulo, a secondary care regionalized facility located in a district of middle-low income in Sao Paulo city, Brazil. The study was approved by the Ethics Committee of the Institution. All patients performed neurological, EEG, brain CT and neuropsychological evaluation which consisted of Raven's Special Progressive Matrices - General and Special Scale (according to different ages), Wechsler Children Intelligence Scale-WISC III with ACID Profile, Trail Making Test A/B, Stroop Test, Bender Visuo-Motor Test, Rey Complex Figure, Rey Auditory Verbal Learning Test-RAVLT, Boston Naming Test, Fluency Verbal for phonological and also conceptual patterns - FAS/Animals and Hooper Visual Organization Test. For academic achievement, we used a Brazilian test for named "Teste do Desempenho Escolar", which evaluates abilities to read, write and calculate according to school grade. RESULTS: There were 2 boys and 6 girls, with ages ranging from 10 yrs. 9 m to 14 yrs. 3 m. Most (7/8) of the patients presented one to two seizures and only three of them received antiepileptic drugs (AEDs). Six had mild EEG focal abnormalities and all had normal brain CT. All were literate, attended regular public schools and scored in a median range for IQ, and seven showed discrete higher scores for the verbal subtests. There were low scores for attention in different modalities in six patients, mainly in alternated attention as well as inhibitory subtests (Stroop test and Trail Making Test part B). Four of the latter cases who showed impairment both in alternated and inhibitory attention were not taking AEDs. Visual memory was impaired in five patients (Rey Complex Figure). Executive functions analysis showed deficits in working memory in five, mostly observed in Digits Indirect Order and Arithmetic tests (WISC III). Reading and writing skills were below the expected average for school grade in six patients according to the achievement scholar performance test utilized. One patient of this series who had the best scores in all tests was taking phenobarbital. CONCLUSIONS: Neuropsychological imbalance between normal IQ and mild dysfunctions such as in attention domain and in some executive abilities like working memory and planning, as well as difficulties in visual memory and in reading and writing, were described in this group of patients with BFSA from community. This may reflect mild higher level neurological dysfunctions in adolescence idiopathic focal seizures probably caused by an underlying dysmaturative epileptogenic process. Although academic problems often have multiple causes, a specific educational approach may be necessary in these adolescents, in order to improve their scholastic achievements, helping in this way, to decrease the stigma associated to epileptic seizures in the community.

APA, Harvard, Vancouver, ISO, and other styles

42

Perez, Anne. "Placement of a feeding button ("one-step button") as the initial procedure D FERGUSON, J HARIG, R KOZAREK, ET AL Cleveland Clinic Foundation, Cleveland, OH; University of Illinois, Chicago; Virginia Mason, Seattle, WA; Harvard Medical School, Massachusetts General Hospital, Boston; and Applied Medical Technology Inc, Independence, OH." Nutrition in Clinical Practice 8, no. 6 (December 1993): 291–92. http://dx.doi.org/10.1177/088453369300800609.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Canfield, Rita. "Alternative/complementary therapies used by persons with HIV disease KM NOKES, J KENDREW, M LONGO Hunter College, City University of New York, Hunter-Bellevue School of Nursing, New York; New York Veterans Administration Medical Center; and New England Deaconess Hospital, Boston." Nutrition in Clinical Practice 11, no. 1 (February 1996): 36. http://dx.doi.org/10.1177/088453369601100114.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

&NA;. "HARVARD MEDICAL SCHOOL ??? BOSTON; MASSACHUSETTS." Investigative Radiology 28, no. 10 (October 1993): 19A. http://dx.doi.org/10.1097/00004424-199310000-00028.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Rao, Gundu H. R. "Biomedicine in the COVID Age: Opportunities, Responses, and Challenges." International Journal of Biomedicine 11, no. 3 (September 9, 2021): 241–49. http://dx.doi.org/10.21103/article11(3)_ra1.

Full text

Abstract:

According to one of the earliest definitions, biomedicine means “clinical medicine based on the principles of physiology and biochemistry.” Clinicians for quite some time preferred the use of the term medical research to describe what they considered the clinical findings pertaining to various issues related to clinical studies. Since the time when the basic molecules of life, deoxyribonucleic acids, were characterized and the genetic code elucidated, there has been great excitement, anticipation, and promise for the development of precision and personalized medicine. However, the progress has been considerably slow and at times disappointing. The unprecedented coronavirus disease created a worldwide panic and exposed all our weaknesses and unpreparedness. It also demonstrated a global demand for better public health infrastructure and preparedness to combat future pandemics. This unprecedented public health crisis acted as a great stimulus for putting together a concerted effort to develop vaccines. According to the experts, the time was right and within 48 hours after the information on the SARS-CoV-2 genome was posted, Moderna scientists had on paper a workable mRNA, which would code for the spike protein. The immune engineers at Moderna as well as BioNTech were able to put together a lipid nanoparticle delivery system for safe delivery of this precious cargo to the appropriate cells. Professor Cody Meissner at Tufts University School of Medicine in Boston says, “It is absolutely astonishing that this happened [COVID Vaccine development] in such a short time—to me, it is equivalent to putting a person on the Moon.” It is indeed a great achievement, and it demonstrated the power of basic science and emerging technologies. The extraordinary success of mRNA vaccines has opened new avenues for mRNA-based therapies. mRNAs, siRNAs, and non-coding miRNAs will play a very important role as novel therapeutics soon. Furthermore, this success has acted as a catalyst for ongoing work on the use of small RNAs for therapeutic purposes. Having said that, I must say that there are a great many challenges that need to be addressed.

APA, Harvard, Vancouver, ISO, and other styles

46

Parkman, Robertson. "Book Review Charles A. Janeway: Pediatrician to the World's Children By Robert J. Haggerty and Frederick H. Lovejoy, Jr. 453 pp., illustrated. Boston, Children's Hospital/Harvard Medical School, 2007. (Distributed by Harvard University Press, Cambridge, MA.) $35. 978-0-674-02380-2." New England Journal of Medicine 357, no. 18 (November 2007): 1877–78. http://dx.doi.org/10.1056/nejmbkrev58769.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Lo, Stephen, Janet Shu, Margot Phillips, Fangui Sun, John L. Berk, and Vaishali Sanchorawala. "Symptoms of Depression and Anxiety Assessed By the SF-36 Questionnaire in Patients with AL Amyloidosis." Blood 126, no. 23 (December 3, 2015): 3299. http://dx.doi.org/10.1182/blood.v126.23.3299.3299.

Full text

Abstract:

Abstract Background: New advances in treatment have improved survival of patients with AL amyloidosis, but research examining the prevalence and significance of anxiety and depression in these patients is limited. Although the association between cardiac involvement and a poorer prognosis has been well established, only early evidence demonstrates influence of cardiac involvement on anxiety and depression. This study examined the prevalence of symptoms of depression and anxiety in patients with AL amyloidosis and whether these symptoms were associated with cardiac involvement and other demographic factors. Methods: This is a retrospective review of cardiac involvement and the Medical Outcomes Study 36-item Short Form General Health Survey (SF-36) of 1414 patients with AL amyloidosis at initial evaluation in the Amyloidosis Center at Boston University School of Medicine and Boston Medical Center from July 1993 to May 2013. Prevalence of self-reported symptoms of depression, symptoms of anxiety, and role limitations due to emotional problems (RE) were derived from the SF-36 questionnaire. Patients were said to have endorsed symptoms of anxiety and depression if they reported a positive score on a 6 point Likert scale to at least one question pertaining to depression and anxiety symptoms in the SF-36 (e.g., "Have you been a very nervous person?"). RE was traditionally scored as a subscale of the SF-36 by averaging the values of the responses. Out of total of 1414 patients, patients with unknown cardiac involvement (n=6) and those who did not answer a single question from each category of interest in the SF-36 (depression n=32; anxiety n=37; RE n=1) were excluded from their respective analysis. A stepwise logistic regression was performed to examine whether self-reported symptoms of depression and anxiety, and RE were associated with cardiac involvement and other demographic factors including gender, age, race, marital status, alcohol consumption, and current smoking status. Results: Of the patients included in the analyses: 659 (46.6%) had cardiac involvement, 523 (38.0%) endorsed depression, 673 (48.6%) endorsed anxiety, and 707 (51.1%) had RE. Patients with cardiac involvement (odds ratio [OR] = 1.31, 95% confidence interval [CI] = 1.05-1.63) and smokers (OR=1.27, CI=1.01-1.59) had significantly greater odds of endorsing symptoms of depression. Men (OR=0.73, CI=0.58-0.90) had significantly lower odds of reporting symptoms of anxiety, while patients with cardiac involvement (OR=1.26, CI=1.02-1.56) and smokers (OR=1.30, CI=1.04-1.62) had significantly increased odds of reporting symptoms of anxiety. Age ≥ 65 years was the only significant predictor of RE (OR=1.44, CI=1.16-1.79). Conclusions: Depression and anxiety symptoms are common among patients with AL amyloidosis and also may have an adverse impact on daily functioning. After controlling for relevant demographic factors, patients with AL amyloidosis and cardiac involvement have greater odds of reporting symptoms of depression and anxiety. Limitations include extrapolating measures of depression and anxiety from a quality of life assessment and not exploring the impact of clinical severity of disease or comorbidities on these symptoms. Further research is needed to study the clinical impact on the treatment and well-being from these experiences of depression and anxiety commonly faced in AL amyloidosis. Indeed, these symptoms of clinical illness - depression and anxiety - can be significant comorbidities that require further attention as part of overall patient care. Disclosures No relevant conflicts of interest to declare.

APA, Harvard, Vancouver, ISO, and other styles

48

Sanchorawala, Vaishali, Gheorghe Doros, Karen Quillen, John Mark Sloan, Anthony C. Shelton, Dina Brauneis, Kathleen T. Finn, and David C. Seldin. "Long-Term Outcome Of Patients With AL Amyloidosis Treated With High-Dose Melphalan and Stem Cell Transplantation: 19 Year Experience At a Single Center." Blood 122, no. 21 (November 15, 2013): 3328. http://dx.doi.org/10.1182/blood.v122.21.3328.3328.

Full text

Abstract:

Abstract Aggressive treatment of AL amyloidosis with high dose intravenous melphalan followed by autologous stem cell transplant (HDM/SCT) is effective in inducing hematologic and clinical remissions associated with prolonged survival. We have performed 593 transplants from July 1994 to December 2012 in the Amyloidosis Center at Boston Medical Center/Boston University School of Medicine. Patients were enrolled in several sequential institutional review board–approved protocols during the 19-year study period. Eligibility criteria for all protocols required biopsy proof of amyloid disease; evidence of a plasma cell dyscrasia and exclusion of other types as appropriate; at least one major affected organ; and adequate measures of cardiac and pulmonary function, and performance status. Functional measures included cardiac ejection fraction 40% or greater, absence of symptomatic pleural effusions, absence of heart failure or arrhythmias resistant to medical management, oxygen saturation of 95% or greater on room air, lung diffusion capacity of 50% or more of predicted, supine systolic blood pressure of 90 mm Hg or greater, and Southwest Oncology Group performance status score of 2 or less unless limited by peripheral neuropathy. Age, renal function, time from diagnosis, prior therapy, and details of the conditioning regimen varied among the trials. Overall, the median age of patients treated with HDM/SCT was 57 years (range, 28-80). Treatment-related mortality (TRM) defined as death occurring within 100 days after SCT occurred in 51 patients, leading to overall TRM of 9% (n=51/593). Additionally, there were 11 deaths during stem cell mobilization and collection phase. No death has occurred since 2005 during stem cell mobilization and collection and TRM has improved to 5% (n=11/235). Total of 324 patients (55%) received full dose melphalan at 200 mg/m2 and 269 (45%) received modified dose melphalan at 100-140 mg/m2 per protocol, based upon age and organ function. Hematologic CR, as defined by international consensus criteria, occurred in 40% (n=202/508) of evaluable patients measured at 6-12 months post SCT; by intention-to-treat the CR rate was 34%. Hematologic CR occurred in 44% (n=129/291) patients who received 200 mg/m2 of HDM compared to 34% (n=73/217) patients who received 100-140 mg/m2 of HDM (chi square p=0.015). Hematologic relapse occurred in 40 patients (20%) with CR at a median of 3.9 years (range, 1.6-12.4). The median overall survival (OS) is 6.7 years with a median follow-up of 4.5 years. The median OS has not been reached for patients achieving a hematologic CR but exceeds 12.4 years, compared to 5.9 years for those not achieving CR (log-rank p<0.001). The median OS for patients following hematologic relapse is 3.5 years. Twenty-five % of patients are alive, up to 19 years after undergoing HDM/SCT. These data highlight the remarkable long-term survival results that can be obtained in patients with AL amyloidosis treated with HDM/SCT. While survival is strongly dependent upon achieving a hematologic CR, the survival of patients who do not achieve a CR and of those who relapse after CR also is notable, suggesting a benefit of treatment. Strategies to improve risk-stratification of patients and reduce TRM, as well as using sequential or combination therapies to increase the CR rate, will likely improve outcomes in the future for patients who just a few years ago were considered to have a rapidly fatal diagnosis. Disclosures: No relevant conflicts of interest to declare.

APA, Harvard, Vancouver, ISO, and other styles

49

Scott, Eggener. "Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, Wong YN, Hahn N, Kohli M, Cooney MM, Dreicer R, Vogelzang NJ, Picus J, Shevrin D, Hussain M, Garcia JA, DiPaola RS. Department of Medicine; Department of Biostatistics and Computational Biology; Dana-Farber Cancer Institute, Boston; Harvard Medical School, Boston; Johns Hopkins University, Baltimore; University of Wisconsin Carbone Cancer Center; School of Medicine and Public Health; Madison; Fox Chase Cancer Center, Temple University Health System, Philadelphia; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis; Mayo Clinic, Rochester, MN; University Hospitals Case Medical Center, Seidman Cancer Center; Cleveland Clinic Taussig Cancer Institute; Both in Cleveland; University of Virginia Cancer Center, Charlottesville; Comprehensive Cancer Centers of Nevada, Las Vegas; Siteman Cancer Center, Washington University School of Medicine, St. Louis; NorthShore University Health System, Evanston, IL; University of Michigan Comprehensive Cancer Center, Ann Arbor; Rutgers Cancer Institute of New Jersey, New Brunswick.N Engl J Med. 2015 Aug 20;373(8):737-46. [Epub 2015 Aug 5]. doi: 10.1056/NEJMoa1503747." Urologic Oncology: Seminars and Original Investigations 35, no. 3 (March 2017): 123. http://dx.doi.org/10.1016/j.urolonc.2016.12.021.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Kelley, Michael. "Effect of intravenous lipid emulsions enriched with γ-linolenic acid on plasma n-6 fatty acids and prostaglandin biosynthesis after burn and endotoxin injury in rats MD KARLSTAD, SJ DEMICHELE, WD LEATHEM, ET AL University of Tennessee Medical Center, Knoxville, TN; Ross Products Division, Abbott Laboratories, Columbus, OH; New England Medical Center Hospitals, Tufts School of Medicine, Boston." Nutrition in Clinical Practice 10, no. 2 (April 1995): 80–81. http://dx.doi.org/10.1177/088453369501000207.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Journal articles on the topic 'Boston University Medical School'

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles